Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) has announced plans to begin a clinical study of its nasally administered Foralumab in COVID-19 patients in Brazil. Proactive analyst Emma Ulker talks to Katie Pilbeam about the trial which will begin shortly with clinical data potentially available before the end of the year. Ulker says the rationale, delivery approach and data are very promising and clearly require substantiation in COVID-19 patients.
Price: 173 GBX
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE
It’s a slow start for the FTSE this Thursday with all eyes on the Bank of England’s meeting later on today for more signs of further stimulus with both the UK employment sector under pressure as well Brexit issues with further tensions between the UK and EU over the divorce deal. The London...
Retail & consumer
Industry & services
Industry & services
